Trial Profile

A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adolescents (Age 12 Years to < 18 Years) With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 03 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

29 May 2025 Status changed from recruiting to active, no longer recruiting.
18 Nov 2024 Trial design evaluating the efficacy, safety, and pharmacokinetics of mavacamten in adolescents with symptomatic obstructive HCM were presented at the American Heart Association Scientific Sessions 2024
11 Nov 2024 According to a Bristol Myers Squibb media release, data from this study will be presented as a Traditional Poster on Monday, Nov. 18, 1:30 PM - 2:30 PM at the American Heart Association (AHA) Annual Scientific Sessions, taking place November 16-18, 2024, in Chicago, Illinois.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com